Novartis Investigative Site
Seoul, South Korea
2,181 recruiting
Showing 1–20 of 174 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals300 enrolled19 locationsNCT07498426
Recruiting
Phase 1Phase 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled10 locationsNCT07288359
Recruiting
Phase 1
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Triple-Negative Breast CancerColorectal, CancerSoft Tissue Sarcoma+3 more
Novartis Pharmaceuticals180 enrolled8 locationsNCT07261631
Recruiting
A Post Marketing Surveillance on Piqray in Korea
Breast Cancer
Novartis Pharmaceuticals900 enrolled19 locationsNCT05293470
Recruiting
Phase 1Phase 2
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals80 enrolled3 locationsNCT07564401
Recruiting
Special Drug Use-results Surveillance of Tafinlar/Mekinist
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals110 enrolled70 locationsNCT06262919
Recruiting
Phase 1
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Advanced Malignancies
Novartis Pharmaceuticals24 enrolled3 locationsNCT07340190
Recruiting
Phase 1Phase 2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled19 locationsNCT07226986
Recruiting
Phase 1
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Novartis Pharmaceuticals63 enrolled1 locationNCT07604324
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled95 locationsNCT06813911
Recruiting
Phase 2Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations
Novartis Pharmaceuticals232 enrolled57 locationsNCT05948943
Recruiting
Phase 3
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Solid TumorHematologic MalignancyAdvanced Malignancies
Novartis Pharmaceuticals50 enrolled15 locationsNCT06401356
Recruiting
Phase 3
Study of Out of Specification for Tisagenlecleucel
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled53 locationsNCT04094311
Recruiting
Phase 1
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Novartis Pharmaceuticals6 enrolled7 locationsNCT07340138
Recruiting
Phase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled13 locationsNCT07357727
Recruiting
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
Leukemia, Chronic Myeloid
Novartis Pharmaceuticals380 enrolled29 locationsNCT07549516
Recruiting
Phase 2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals104 enrolled32 locationsNCT06997588
Recruiting
Phase 1
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer (mCRPC)
Novartis Pharmaceuticals15 enrolled4 locationsNCT07174063
Recruiting
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy
Secondary Malignancies of T-cell Origin
Novartis Pharmaceuticals30 enrolled4 locationsNCT07378969
Recruiting
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals160 enrolled15 locationsNCT06486779